Walleye Capital LLC decreased its stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 94.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,000 shares of the company's stock after selling 241,881 shares during the quarter. Walleye Capital LLC's holdings in AbCellera Biologics were worth $44,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of AbCellera Biologics by 1.5% during the third quarter. State Street Corp now owns 323,229 shares of the company's stock worth $840,000 after acquiring an additional 4,679 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of AbCellera Biologics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company's stock worth $184,000 after acquiring an additional 5,955 shares in the last quarter. DKM Wealth Management Inc. purchased a new stake in shares of AbCellera Biologics during the fourth quarter worth $29,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of AbCellera Biologics during the fourth quarter worth $36,000. Finally, B. Riley Wealth Advisors Inc. raised its holdings in shares of AbCellera Biologics by 58.1% during the third quarter. B. Riley Wealth Advisors Inc. now owns 34,000 shares of the company's stock worth $88,000 after acquiring an additional 12,500 shares in the last quarter. Institutional investors and hedge funds own 61.42% of the company's stock.
AbCellera Biologics Stock Performance
Shares of AbCellera Biologics stock traded down $0.12 during trading on Thursday, reaching $2.49. The company's stock had a trading volume of 3,453,268 shares, compared to its average volume of 2,691,970. The business's fifty day moving average price is $2.40 and its 200-day moving average price is $2.77. The firm has a market cap of $741.99 million, a price-to-earnings ratio of -4.08 and a beta of 0.50. AbCellera Biologics Inc. has a one year low of $1.89 and a one year high of $4.34.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. KeyCorp increased their price objective on AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Stifel Nicolaus cut their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, Benchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Monday, March 3rd.
Check Out Our Latest Stock Report on ABCL
AbCellera Biologics Company Profile
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
